Twist Bioscience (TWST) Financials

$29.52 +0.63 (+2.18%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$29.46 -0.06 (-0.20%)

As of 05/30/2025 07:40 PM Eastern

Annual Income Statements for Twist Bioscience

This table shows Twist Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	9/30/2024	9/30/2023	9/30/2022	9/30/2021	9/30/2020	9/30/2019	9/30/2018	9/30/2017
Net Income / (Loss) Attributable to Common Shareholders	-209	-205	-218	-152	-140	-108	-71	-59
Consolidated Net Income / (Loss)	-209	-205	-218	-152	-140	-108	-71	-59
Net Income / (Loss) Continuing Operations	-209	-205	-218	-152	-140	-108	-71	-59
Total Pre-Tax Income	-208	-203	-228	-154	-140	-107	-71	-59
Total Operating Income	-221	-217	-235	-153	-140	-109	-71	-58
Total Gross Profit	133	90	84	52	29	6.96	-6.76	-13
Total Revenue	313	245	204	132	90	54	25	11
Operating Revenue	313	245	204	132	90	54	25	11
Total Cost of Revenue	180	155	119	81	61	47	32	24
Operating Cost of Revenue	180	155	119	81	61	47	32	24
Total Operating Expenses	354	307	319	204	169	116	64	45
Selling, General & Admin Expense	218	190	213	136	103	80	43	26
Research & Development Expense	91	107	120	69	43	36	20	19
Other Operating Expenses / (Income)	0.00	-5.91	-14	-0.53	0.00	0.00	-	-
Impairment Charge	45	6.79	0.00	-	-	-	-	-
Restructuring Charge	0.00	9.38	0.00	0.00	-	-	-	-
Total Other Income / (Expense), net	13	14	6.50	-1.30	0.53	1.47	-0.44	-0.55
Interest Expense	0.03	0.01	0.08	0.37	0.79	1.29	1.31	0.91
Interest & Investment Income	15	14	7.67	0.44	1.50	3.03	1.00	0.41
Other Income / (Expense), net	-2.65	-0.67	-1.09	-1.37	-0.18	-0.27	-0.12	-0.06
Income Tax Expense	0.56	1.15	-10	-1.93	0.38	0.29	0.24	0.28
Basic Earnings per Share	($3.60)	($3.60)	($4.04)	($3.15)	($3.57)	($3.92)	($25.51)	($24.49)
Weighted Average Basic Shares Outstanding	58.02M	56.89M	53.89M	48.25M	39.19M	27.46M	2.79M	2.42M
Diluted Earnings per Share	($3.60)	($3.60)	($4.04)	($3.15)	($3.57)	($3.92)	($25.51)	($24.49)
Weighted Average Diluted Shares Outstanding	58.02M	56.89M	53.89M	48.25M	39.19M	27.46M	2.79M	2.42M
Weighted Average Basic & Diluted Shares Outstanding	59.36M	57.67M	56.57M	48.25M	39.19M	27.46M	2.79M	2.42M

This table shows Twist Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-39	-32	-35	-86	-45	-43	-46	-57	-59	-42	-51
Consolidated Net Income / (Loss)	-39	-32	-35	-86	-45	-43	-46	-57	-59	-42	-51
Net Income / (Loss) Continuing Operations	-39	-32	-35	-86	-45	-43	-46	-57	-59	-42	-51
Total Pre-Tax Income	-39	-31	-35	-85	-45	-43	-46	-57	-58	-42	-51
Total Operating Income	-42	-35	-36	-89	-49	-47	-50	-61	-62	-45	-57
Total Gross Profit	46	43	38	35	31	29	25	22	19	25	26
Total Revenue	93	89	85	81	75	71	67	64	60	54	57
Operating Revenue	93	89	85	81	75	71	67	64	60	54	57
Total Cost of Revenue	47	46	46	46	44	43	42	42	42	29	32
Operating Cost of Revenue	47	46	46	46	44	43	42	42	42	29	32
Total Operating Expenses	88	77	74	124	80	76	75	83	80	69	83
Selling, General & Admin Expense	64	56	53	57	56	53	47	46	54	42	54
Research & Development Expense	24	21	21	22	24	23	24	25	27	31	30
Total Other Income / (Expense), net	2.41	3.15	1.29	3.54	3.74	4.09	3.65	4.01	3.16	2.88	6.05
Interest Expense	0.14	0.02	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03
Interest & Investment Income	2.80	3.24	3.62	3.66	3.94	4.12	3.89	3.97	3.46	3.04	6.53
Other Income / (Expense), net	-0.25	-0.07	-2.30	-0.12	-0.20	-0.03	-0.25	0.04	-0.31	-0.16	-0.46
Income Tax Expense	0.18	0.10	-0.10	0.19	0.35	0.12	-0.22	0.62	0.68	0.08	0.29
Basic Earnings per Share	($0.66)	($0.53)	($0.59)	($1.47)	($0.79)	($0.75)	($0.81)	($1.01)	($1.04)	($0.74)	($0.92)
Weighted Average Basic Shares Outstanding	59.65M	59.16M	58.02M	58.15M	57.78M	57.50M	56.89M	57.04M	56.78M	56.44M	53.89M
Diluted Earnings per Share	($0.66)	($0.53)	($0.59)	($1.47)	($0.79)	($0.75)	($0.81)	($1.01)	($1.04)	($0.74)	($0.92)
Weighted Average Diluted Shares Outstanding	59.65M	59.16M	58.02M	58.15M	57.78M	57.50M	56.89M	57.04M	56.78M	56.44M	53.89M
Weighted Average Basic & Diluted Shares Outstanding	59.92M	59.65M	59.36M	58.59M	58.23M	57.82M	57.67M	57.40M	57.15M	56.86M	56.57M

This table details how cash moves in and out of Twist Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	9/30/2024	9/30/2023	9/30/2022	9/30/2021	9/30/2020	9/30/2019	9/30/2018	9/30/2017
Net Change in Cash & Equivalents	-60	-91	-87	373	47	-34	50	2.51
Net Cash From Operating Activities	-64	-142	-124	-112	-142	-88	-66	-51
Net Cash From Continuing Operating Activities	-64	-143	-124	-113	-142	-88	-66	-51
Net Income / (Loss) Continuing Operations	-209	-205	-218	-152	-140	-108	-71	-59
Consolidated Net Income / (Loss)	-209	-205	-218	-152	-140	-108	-71	-59
Depreciation Expense	31	29	17	9.75	6.68	6.11	5.73	5.02
Non-Cash Adjustments To Reconcile Net Income	98	40	97	39	16	12	3.26	3.02
Changes in Operating Assets and Liabilities, net	15	-1.01	-20	-9.38	-25	3.00	-4.22	-0.13
Net Cash From Investing Activities	-3.07	51	-233	156	-115	-105	27	-9.99
Net Cash From Continuing Investing Activities	-3.07	51	-233	156	-115	-105	27	-9.99
Purchase of Property, Plant & Equipment	-5.08	-28	-102	-27	-9.87	-15	-3.69	-6.59
Acquisitions	0.00	0.00	-14	-0.48	0.00	0.00	-	-
Purchase of Investments	-52	-76	-218	-59	-203	-178	-3.52	-41
Sale and/or Maturity of Investments	54	155	100	242	98	88	35	37
Net Cash From Financing Activities	6.89	0.91	271	329	304	159	89	64
Net Cash From Continuing Financing Activities	6.89	0.91	271	329	304	159	89	64
Repayment of Debt	0.00	0.00	-1.56	-3.33	-3.33	-2.50	0.00	-4.17
Repurchase of Common Equity	-3.98	-4.41	-7.75	-11	-2.42	0.00	-2.36	0.00
Issuance of Common Equity	11	1.38	280	338	306	158	0.33	0.21
Effect of Exchange Rate Changes	0.13	-0.03	-0.32	0.02	0.02	0.03	-	-
Cash Interest Paid	0.00	0.00	0.01	0.17	0.44	0.78	0.75	0.70
Cash Income Taxes Paid	0.34	0.42	0.25	0.10	0.17	0.29	0.18	0.01

This table details how cash moves in and out of Twist Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-11	-5.07	-13	-4.18	-23	-20	-23	-5.72	-1.53	-61	2.44
Net Cash From Operating Activities	-13	-21	-15	-6.38	-19	-23	-21	-23	-44	-54	-1.27
Net Cash From Continuing Operating Activities	-13	-21	-15	-6.38	-19	-23	-21	-23	-44	-54	-0.28
Net Income / (Loss) Continuing Operations	-39	-32	-35	-86	-45	-43	-46	-57	-59	-42	-51
Consolidated Net Income / (Loss)	-39	-32	-35	-86	-45	-43	-46	-57	-59	-42	-51
Depreciation Expense	6.40	6.38	6.66	8.30	8.30	8.17	8.50	8.49	7.03	5.29	4.95
Non-Cash Adjustments To Reconcile Net Income	21	12	14	58	14	11	22	13	9.69	-5.92	33
Changes in Operating Assets and Liabilities, net	-1.22	-8.19	-1.14	13	3.46	0.53	0.44	12	-1.85	-12	-0.54
Net Cash From Investing Activities	-1.43	-1.54	-1.29	-0.71	-5.24	4.17	-2.25	19	41	-6.97	2.78
Net Cash From Continuing Investing Activities	-1.43	-1.54	-1.29	-0.71	-5.24	4.17	-2.25	19	41	-6.97	2.78
Purchase of Property, Plant & Equipment	-4.14	-2.27	-2.00	-0.97	-0.60	-1.51	-2.39	-4.51	-9.05	-12	-16
Purchase of Investments	-4.93	-21	-21	-1.75	-11	-18	-18	-7.82	-28	-23	-
Sale and/or Maturity of Investments	7.65	21	22	2.00	6.00	24	18	31	78	28	25
Net Cash From Financing Activities	3.20	18	3.63	2.91	1.83	-1.47	0.44	-0.66	1.53	-0.40	1.24
Net Cash From Continuing Financing Activities	3.20	18	3.63	2.91	1.83	-1.47	0.44	-0.66	1.53	-0.40	1.24
Repurchase of Common Equity	-0.01	-0.01	-0.01	-0.01	-1.54	-2.42	-1.13	-1.01	-1.26	-1.00	-1.62
Issuance of Common Equity	0.77	2.95	5.68	2.92	1.32	0.95	0.17	0.35	0.25	0.60	5.26
Effect of Exchange Rate Changes	0.10	-0.05	0.07	0.00	-0.07	0.12	-0.05	-0.32	0.07	0.27	-0.32
Cash Income Taxes Paid	0.01	0.00	-0.02	0.02	0.30	0.04	0.18	0.10	0.09	0.05	0.12

This table presents Twist Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	9/30/2024	9/30/2023	9/30/2022	9/30/2021	9/30/2020	9/30/2019	9/30/2018
Total Assets	614	776	961	702	399	187	116
Total Current Assets	347	424	596	546	335	160	96
Cash & Equivalents	226	286	379	466	94	47	81
Short-Term Investments	50	50	126	12	196	91	0.00
Accounts Receivable	35	44	40	29	26	12	5.42
Inventories, net	24	32	39	32	12	7.33	6.03
Prepaid Expenses	11	12	12	8.28	6.20	2.59	3.47
Plant, Property, & Equipment, net	103	132	139	44	25	21	12
Total Noncurrent Assets	165	220	225	111	39	6.02	7.79
Goodwill	86	86	86	22	1.14	1.14	1.14
Intangible Assets	14	54	60	18	0.31	0.51	0.71
Other Noncurrent Operating Assets	65	80	80	71	37	4.38	5.94
Total Liabilities & Shareholders' Equity	614	776	961	702	399	187	116
Total Liabilities	142	153	172	121	63	35	27
Total Current Liabilities	71	73	91	63	36	30	19
Accounts Payable	1.63	14	20	15	4.83	9.76	7.53
Accrued Expenses	15	11	10	6.44	3.90	5.97	2.17
Current Employee Benefit Liabilities	34	26	27	22	15	10	5.40
Other Current Liabilities	21	23	33	18	9.02	0.82	0.94
Total Noncurrent Liabilities	71	80	81	58	27	4.56	8.19
Noncurrent Deferred Revenue	0.00	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	71	80	81	58	25	0.16	0.98
Commitments & Contingencies	0.00	0.00	0.00	0.00	-	0.00	0.00
Total Equity & Noncontrolling Interests	473	623	789	581	336	152	-201
Total Preferred & Common Equity	473	623	789	581	336	152	-201
Total Common Equity	473	623	789	581	336	152	-201
Common Stock	1,715	1,657	1,620	1,191	795	470	9.35
Retained Earnings	-1,242	-1,033	-828	-611	-458	-319	-211
Accumulated Other Comprehensive Income / (Loss)	-0.52	-0.76	-1.84	0.55	0.09	0.18	0.09

This table presents Twist Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	12/31/2024	6/30/2024	3/31/2024	12/31/2023	6/30/2023	3/31/2023	12/31/2022	6/30/2022
Total Assets	596	609	638	703	733	810	854	910	980
Total Current Assets	338	345	362	372	390	446	489	542	624
Cash & Equivalents	210	221	239	243	266	307	315	317	376
Short-Term Investments	47	49	50	50	45	50	72	122	151
Accounts Receivable	50	39	32	36	35	43	48	44	41
Inventories, net	21	24	28	30	31	36	40	45	43
Prepaid Expenses	10	12	12	12	13	9.46	14	14	12
Plant, Property, & Equipment, net	97	101	106	121	126	141	147	145	127
Total Noncurrent Assets	160	163	170	210	216	224	218	223	229
Goodwill	86	86	86	86	86	86	86	86	86
Intangible Assets	14	14	15	52	53	56	57	58	61
Other Noncurrent Operating Assets	60	63	69	72	77	82	75	79	82
Total Liabilities & Shareholders' Equity	596	609	638	703	733	810	854	910	980
Total Liabilities	156	153	147	143	143	153	150	164	159
Total Current Liabilities	75	70	74	67	65	73	72	84	93
Accounts Payable	8.06	7.50	6.63	7.70	9.26	12	13	20	21
Accrued Expenses	20	20	15	15	14	10	11	10	9.50
Current Employee Benefit Liabilities	25	22	32	25	21	27	24	23	28
Other Current Liabilities	22	20	21	20	21	23	23	30	34
Total Noncurrent Liabilities	81	83	73	75	78	80	78	80	66
Noncurrent Deferred Revenue	15	15	-	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	66	68	73	75	78	80	78	80	66
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	440	456	491	560	590	658	704	746	821
Total Preferred & Common Equity	440	456	491	560	590	658	704	746	821
Total Common Equity	440	456	491	560	590	658	704	746	821
Common Stock	1,754	1,730	1,699	1,682	1,667	1,645	1,633	1,617	1,599
Retained Earnings	-1,313	-1,274	-1,207	-1,122	-1,076	-987	-929	-870	-777
Accumulated Other Comprehensive Income / (Loss)	-0.66	-0.65	-0.74	-0.66	-0.57	-0.64	0.11	-0.61	-1.38

This table displays calculated financial ratios and metrics derived from Twist Bioscience's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	9/30/2024	9/30/2023	9/30/2022	9/30/2021	9/30/2020	9/30/2019	9/30/2018	9/30/2017
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	27.69%	20.41%	53.83%	46.87%	65.67%	113.89%	136.16%	0.00%
EBITDA Growth	1.22%	11.36%	-51.40%	-8.43%	-28.51%	-60.83%	-21.01%	0.00%
EBIT Growth	-2.60%	7.65%	-53.06%	-9.86%	-28.54%	-54.38%	-20.74%	0.00%
NOPAT Growth	-1.69%	7.50%	-53.72%	-9.03%	-28.69%	-54.27%	-20.65%	0.00%
Net Income Growth	-2.01%	6.08%	-43.24%	-8.70%	-29.96%	-51.14%	-20.11%	0.00%
EPS Growth	0.00%	10.89%	-28.25%	11.76%	8.93%	84.63%	-4.17%	0.00%
Operating Cash Flow Growth	55.01%	-14.54%	-10.82%	21.10%	-61.77%	-32.91%	-28.97%	0.00%
Free Cash Flow Firm Growth	58.70%	55.09%	-114.59%	-25.98%	-59.42%	-18.49%	0.00%	0.00%
Invested Capital Growth	-31.61%	0.91%	172.14%	104.94%	134.92%	20.45%	0.00%	0.00%
Revenue Q/Q Growth	6.02%	4.09%	10.51%	4.35%	22.75%	15.58%	0.00%	0.00%
EBITDA Q/Q Growth	5.03%	2.32%	0.08%	-13.66%	5.80%	-13.00%	0.00%	0.00%
EBIT Q/Q Growth	5.10%	3.10%	-7.50%	-12.28%	5.11%	-12.15%	0.00%	0.00%
NOPAT Q/Q Growth	5.99%	3.02%	-7.84%	-11.57%	5.15%	-12.23%	0.00%	0.00%
Net Income Q/Q Growth	5.26%	2.33%	-4.75%	-12.52%	4.68%	-11.82%	0.00%	0.00%
EPS Q/Q Growth	5.76%	2.97%	-2.28%	-17.54%	12.93%	59.25%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	7.75%	-15.80%	21.24%	-9.35%	-1.31%	-8.20%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	2.88%	5.76%	2.22%	-9.48%	-3.20%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-2.69%	-4.46%	-2.96%	11.89%	19.46%	-4.24%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	42.61%	36.61%	41.38%	39.08%	31.85%	12.80%	-26.59%	-123.09%
EBITDA Margin	-61.36%	-79.32%	-107.75%	-109.48%	-148.30%	-191.18%	-254.24%	-496.15%
Operating Margin	-70.56%	-88.60%	-115.33%	-115.41%	-155.47%	-200.15%	-277.50%	-543.16%
EBIT Margin	-71.41%	-88.87%	-115.87%	-116.45%	-155.67%	-200.63%	-277.97%	-543.67%
Profit (Net Income) Margin	-66.69%	-83.48%	-107.02%	-114.94%	-155.31%	-197.98%	-280.16%	-550.85%
Tax Burden Percent	100.27%	100.57%	95.44%	98.75%	100.27%	100.27%	100.34%	100.47%
Interest Burden Percent	93.15%	93.41%	96.78%	99.96%	99.49%	98.41%	100.44%	100.84%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-63.97%	-53.20%	-84.51%	-137.50%	-269.74%	-383.56%	-548.12%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-46.30%	-40.70%	-73.60%	-125.63%	-249.59%	-352.31%	-486.62%	0.00%
Return on Net Nonoperating Assets (RNNOA)	25.88%	24.24%	52.71%	104.33%	212.43%	294.27%	388.15%	0.00%
Return on Equity (ROE)	-38.08%	-28.97%	-31.80%	-33.17%	-57.31%	-89.30%	-159.97%	0.00%
Cash Return on Invested Capital (CROIC)	-26.42%	-54.11%	-177.03%	-206.32%	-350.31%	-402.12%	-748.12%	0.00%
Operating Return on Assets (OROA)	-32.14%	-25.07%	-28.36%	-27.99%	-47.88%	-72.07%	-61.04%	0.00%
Return on Assets (ROA)	-30.02%	-23.55%	-26.19%	-27.63%	-47.77%	-71.12%	-61.52%	0.00%
Return on Common Equity (ROCE)	-38.08%	-28.97%	-31.80%	-33.17%	-57.31%	18.27%	361.79%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-44.16%	-32.82%	-27.60%	-26.19%	-41.61%	-70.80%	35.37%	0.00%
Net Operating Profit after Tax (NOPAT)	-155	-152	-164	-107	-98	-76	-49	-41
NOPAT Margin	-49.39%	-62.02%	-80.73%	-80.79%	-108.83%	-140.10%	-194.25%	-380.21%
Net Nonoperating Expense Percent (NNEP)	-17.67%	-12.50%	-10.91%	-11.87%	-20.15%	-31.25%	-61.50%	0.00%
Cost of Revenue to Revenue	57.39%	63.39%	58.62%	60.92%	68.15%	87.20%	126.59%	223.09%
SG&A Expenses to Revenue	69.78%	77.41%	104.61%	102.70%	114.61%	147.33%	170.88%	242.04%
R&D to Revenue	29.03%	43.61%	59.10%	52.20%	47.73%	65.61%	80.02%	178.03%
Operating Expenses to Revenue	113.17%	125.20%	156.71%	154.49%	187.32%	212.94%	250.90%	420.07%
Earnings before Interest and Taxes (EBIT)	-223	-218	-236	-154	-140	-109	-71	-59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-192	-194	-219	-145	-134	-104	-65	-53
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.60	1.87	2.52	9.08	10.09	5.11	0.00	0.00
Price to Tangible Book Value (P/TBV)	7.11	2.41	3.09	9.76	10.13	5.17	0.00	0.00
Price to Revenue (P/Rev)	8.46	4.74	9.76	39.84	37.66	14.30	2.75	6.50
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	12.08	2.88	5.21	45.89	60.94	29.81	16.06	0.00
Enterprise Value to Revenue (EV/Rev)	7.57	3.37	7.28	36.25	34.49	11.90	11.38	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.01	0.05	0.11	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.03	0.08	0.00
Financial Leverage	-0.56	-0.60	-0.72	-0.83	-0.85	-0.84	-0.80	0.00
Leverage Ratio	1.27	1.23	1.21	1.20	1.20	1.26	1.30	0.00
Compound Leverage Factor	1.18	1.15	1.18	1.20	1.19	1.24	1.31	0.00
Debt to Total Capital	0.00%	0.00%	0.00%	0.27%	1.39%	4.84%	9.84%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.27%	0.98%	2.09%	2.53%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.41%	2.75%	7.31%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	294.07%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	99.73%	98.61%	95.16%	-203.91%	0.00%
Debt to EBITDA	0.00	0.00	0.00	-0.01	-0.04	-0.07	-0.15	0.00
Net Debt to EBITDA	0.00	0.00	0.00	3.29	2.14	1.25	1.10	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-0.01	-0.04	-0.11	0.00
Debt to NOPAT	0.00	0.00	0.00	-0.01	-0.05	-0.10	-0.20	0.00
Net Debt to NOPAT	0.00	0.00	0.00	4.46	2.91	1.71	1.44	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-0.01	-0.06	-0.15	0.00
Altman Z-Score	8.23	2.63	5.76	25.16	30.87	10.18	-1.97	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	120.46%	326.16%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	4.88	5.79	6.58	8.67	9.29	5.28	5.16	0.00
Quick Ratio	4.38	5.19	6.01	8.03	8.78	4.95	4.65	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-64	-155	-344	-160	-127	-80	-67	0.00
Operating Cash Flow to CapEx	-1,262.69%	-512.88%	-122.12%	-414.78%	-1,441.58%	-596.75%	-1,802.34%	-810.70%
Free Cash Flow to Firm to Interest Expense	-2,201.82	-30,922.66	-4,303.13	-437.12	-161.81	-61.73	-51.34	0.00
Operating Cash Flow to Interest Expense	-2,210.14	-28,494.80	-1,554.81	-305.84	-180.76	-67.96	-50.39	-56.69
Operating Cash Flow Less CapEx to Interest Expense	-2,385.17	-34,050.60	-2,828.03	-379.58	-193.29	-79.35	-53.19	-63.68
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.28	0.24	0.24	0.31	0.36	0.22	0.00
Accounts Receivable Turnover	7.93	5.81	5.91	4.82	4.68	6.21	4.69	0.00
Inventory Turnover	6.40	4.35	3.36	3.66	6.26	7.10	5.34	0.00
Fixed Asset Turnover	2.67	1.81	2.22	3.80	3.89	3.28	2.06	0.00
Accounts Payable Turnover	22.91	9.10	6.82	8.17	8.42	5.49	4.27	0.00
Days Sales Outstanding (DSO)	46.05	62.81	61.72	75.75	77.94	58.80	77.79	0.00
Days Inventory Outstanding (DIO)	57.04	83.83	108.75	99.80	58.31	51.40	68.35	0.00
Days Payable Outstanding (DPO)	15.93	40.10	53.52	44.66	43.36	66.54	85.40	0.00
Cash Conversion Cycle (CCC)	87.15	106.53	116.95	130.89	92.89	43.67	60.75	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	196	287	284	105	51	22	18	0.00
Invested Capital Turnover	1.30	0.86	1.05	1.70	2.48	2.74	2.82	0.00
Increase / (Decrease) in Invested Capital	-91	2.60	180	54	29	3.69	18	0.00
Enterprise Value (EV)	2,371	826	1,481	4,796	3,108	647	289	0.00
Market Capitalization	2,647	1,163	1,986	5,273	3,393	778	70	70
Book Value per Share	$8.07	$10.86	$14.01	$11.78	$7.53	$4.67	($72.12)	$0.00
Tangible Book Value per Share	$6.36	$8.42	$11.42	$10.96	$7.50	$4.62	($72.78)	$0.00
Total Capital	473	623	789	582	341	160	99	0.00
Total Debt	0.00	0.00	0.00	1.55	4.74	7.73	9.72	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	1.40	4.40	7.22	0.00
Net Debt	-276	-336	-505	-476	-285	-130	-71	0.00
Capital Expenditures (CapEx)	5.08	28	102	27	9.87	15	3.67	6.33
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.63	15	0.85	7.13	12	-4.99	-1.12	0.00
Debt-free Net Working Capital (DFNWC)	276	351	506	485	302	133	80	0.00
Net Working Capital (NWC)	276	351	506	483	299	130	77	0.00
Net Nonoperating Expense (NNE)	54	53	54	45	42	31	22	18
Net Nonoperating Obligations (NNO)	-276	-336	-505	-476	-285	-130	-71	0.00
Total Depreciation and Amortization (D&A)	31	23	17	9.22	6.65	5.14	6.04	5.12
Debt-free, Cash-free Net Working Capital to Revenue	-0.20%	5.92%	0.42%	5.39%	13.51%	-9.18%	-4.42%	0.00%
Debt-free Net Working Capital to Revenue	88.11%	143.17%	248.48%	366.50%	335.38%	244.76%	313.19%	0.00%
Net Working Capital to Revenue	88.11%	143.17%	248.48%	365.32%	331.68%	238.63%	303.35%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.60)	($3.60)	$0.00	($3.15)	($3.57)	($3.92)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	58.02M	56.89M	0.00	49.63M	45.15M	33.12M	0.00	0.00
Adjusted Diluted Earnings per Share	($3.60)	($3.60)	$0.00	($3.15)	($3.57)	($3.92)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	58.02M	56.89M	0.00	49.63M	45.15M	33.12M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($3.15)	($3.57)	($3.92)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	59.36M	57.67M	0.00	48.25M	39.19M	27.46M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-123	-141	-164	-107	-82	-76	-49	-41
Normalized NOPAT Margin	-39.34%	-57.40%	-80.73%	-80.79%	-91.35%	-140.10%	-194.25%	-380.21%
Pre Tax Income Margin	-66.51%	-83.01%	-112.14%	-116.39%	-154.88%	-197.44%	-279.21%	-548.25%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-7,706.24	-43,565.20	-2,948.29	-419.88	-178.22	-84.32	-53.83	-64.68
NOPAT to Interest Expense	-5,330.40	-30,402.26	-2,054.29	-291.30	-124.59	-58.88	-37.62	-45.23
EBIT Less CapEx to Interest Expense	-7,881.28	-49,121.00	-4,221.50	-493.62	-190.76	-95.71	-56.63	-71.67
NOPAT Less CapEx to Interest Expense	-5,505.44	-35,958.06	-3,327.50	-365.04	-137.13	-70.27	-40.41	-52.23
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-1.90%	-2.15%	-3.56%	-7.13%	-1.73%	0.00%	-3.31%	0.00%

This table displays calculated financial ratios and metrics derived from Twist Bioscience's official financial filings.

Metric	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	23.23%	24.08%	26.53%	27.81%	25.13%	31.81%	16.82%	13.59%	25.04%	29.09%	51.01%
EBITDA Growth	13.18%	27.05%	24.30%	-54.53%	25.73%	1.67%	20.09%	8.24%	3.79%	25.41%	-32.67%
EBIT Growth	14.82%	26.16%	23.86%	-46.60%	20.75%	-4.96%	12.17%	1.06%	-1.47%	20.16%	-40.26%
NOPAT Growth	14.99%	26.25%	28.07%	-46.30%	20.68%	-5.26%	11.89%	0.62%	-1.37%	20.22%	-42.85%
Net Income Growth	13.55%	26.54%	25.06%	-49.09%	23.10%	-2.83%	9.53%	5.16%	2.49%	8.21%	-23.94%
EPS Growth	16.46%	29.33%	27.16%	-45.54%	24.04%	-1.35%	11.96%	6.48%	7.96%	18.68%	-10.84%
Operating Cash Flow Growth	33.14%	6.73%	26.00%	72.76%	56.14%	57.51%	-1,534.10%	31.39%	-4.60%	-15.90%	96.36%
Free Cash Flow Firm Growth	258.63%	1,768.70%	273.83%	173.07%	115.19%	96.57%	82.85%	79.44%	58.09%	39.91%	-169.98%
Invested Capital Growth	-31.42%	-33.63%	-31.61%	-32.85%	-15.65%	-9.34%	0.91%	2.50%	22.15%	41.45%	172.14%
Revenue Q/Q Growth	4.60%	4.73%	3.98%	8.18%	5.32%	6.80%	5.03%	5.92%	10.95%	-5.35%	2.13%
EBITDA Q/Q Growth	-24.97%	10.58%	60.76%	-97.97%	-5.01%	7.22%	19.89%	4.85%	-39.04%	24.60%	8.01%
EBIT Q/Q Growth	-20.45%	9.46%	56.94%	-81.39%	-4.42%	6.65%	17.09%	1.94%	-38.30%	21.88%	6.61%
NOPAT Q/Q Growth	-19.96%	3.88%	59.47%	-81.89%	-4.07%	6.25%	17.55%	1.39%	-38.11%	21.52%	7.02%
Net Income Q/Q Growth	-24.48%	8.83%	59.50%	-88.10%	-5.78%	7.00%	19.43%	2.98%	-41.44%	18.18%	15.54%
EPS Q/Q Growth	-24.53%	10.17%	59.86%	-86.08%	-5.33%	7.41%	19.80%	2.88%	-40.54%	19.57%	14.81%
Operating Cash Flow Q/Q Growth	39.40%	-39.87%	-140.20%	67.16%	15.45%	-10.96%	11.57%	47.14%	18.09%	-4,167.56%	96.29%
Free Cash Flow Firm Q/Q Growth	-21.28%	6.16%	79.75%	138.74%	466.28%	88.94%	24.44%	50.38%	17.20%	44.76%	9.39%
Invested Capital Q/Q Growth	-1.16%	-5.69%	-2.69%	-24.39%	-4.34%	-2.83%	-4.46%	-5.02%	2.81%	8.16%	-2.96%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	49.60%	48.29%	45.14%	43.30%	41.01%	40.51%	36.63%	34.35%	30.76%	45.72%	44.88%
EBITDA Margin	-38.16%	-31.94%	-37.41%	-99.11%	-54.16%	-54.32%	-62.52%	-81.97%	-91.25%	-72.81%	-91.40%
Operating Margin	-44.79%	-39.05%	-42.55%	-109.16%	-64.92%	-65.70%	-74.85%	-95.36%	-102.42%	-82.28%	-99.24%
EBIT Margin	-45.06%	-39.13%	-45.26%	-109.30%	-65.19%	-65.75%	-75.22%	-95.29%	-102.93%	-82.57%	-100.04%
Profit (Net Income) Margin	-42.38%	-35.61%	-40.91%	-105.04%	-60.41%	-60.15%	-69.08%	-90.05%	-98.30%	-77.10%	-89.20%
Tax Burden Percent	100.45%	100.31%	99.72%	100.22%	100.76%	100.28%	99.52%	101.10%	101.16%	100.18%	100.57%
Interest Burden Percent	93.64%	90.74%	90.63%	95.89%	91.97%	91.24%	92.27%	93.47%	94.41%	93.21%	88.65%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-48.47%	-38.90%	-38.57%	-89.84%	-43.26%	-41.15%	-44.95%	-52.97%	-56.80%	-47.34%	-72.72%
ROIC Less NNEP Spread (ROIC-NNEP)	-44.75%	-36.38%	-35.50%	-82.63%	-39.95%	-38.45%	-42.30%	-49.61%	-53.57%	-44.84%	-70.41%
Return on Net Nonoperating Assets (RNNOA)	24.63%	20.24%	19.85%	46.51%	21.52%	21.57%	25.19%	29.69%	33.91%	27.69%	50.43%
Return on Equity (ROE)	-23.84%	-18.66%	-18.73%	-43.33%	-21.74%	-19.57%	-19.76%	-23.27%	-22.89%	-19.65%	-22.29%
Cash Return on Invested Capital (CROIC)	-25.34%	-22.48%	-26.42%	-26.19%	-32.67%	-42.60%	-54.11%	-55.29%	-74.54%	-93.91%	-177.03%
Operating Return on Assets (OROA)	-24.13%	-19.26%	-20.37%	-44.55%	-23.24%	-21.00%	-21.22%	-25.07%	-25.01%	-21.01%	-24.49%
Return on Assets (ROA)	-22.70%	-17.53%	-18.41%	-42.82%	-21.54%	-19.21%	-19.49%	-23.69%	-23.88%	-19.62%	-21.83%
Return on Common Equity (ROCE)	-23.84%	-18.66%	-18.73%	-43.33%	-21.74%	-19.57%	-19.76%	-23.27%	-22.89%	-19.65%	-22.29%
Return on Equity Simple (ROE_SIMPLE)	-43.43%	-43.28%	0.00%	-44.86%	-34.30%	-34.88%	0.00%	-31.86%	-30.20%	-28.69%	0.00%
Net Operating Profit after Tax (NOPAT)	-29	-24	-25	-62	-34	-33	-35	-43	-43	-31	-40
NOPAT Margin	-31.35%	-27.34%	-29.78%	-76.41%	-45.45%	-45.99%	-52.40%	-66.75%	-71.69%	-57.59%	-69.47%
Net Nonoperating Expense Percent (NNEP)	-3.72%	-2.52%	-3.08%	-7.22%	-3.31%	-2.70%	-2.65%	-3.36%	-3.23%	-2.50%	-2.30%
Return On Investment Capital (ROIC_SIMPLE)	-6.61%	-5.32%	-	-	-	-5.57%	-	-	-	-	-
Cost of Revenue to Revenue	50.40%	51.71%	54.86%	56.70%	58.99%	59.49%	63.37%	65.65%	69.24%	54.28%	55.12%
SG&A Expenses to Revenue	68.62%	63.32%	62.73%	69.72%	73.87%	73.90%	70.79%	72.26%	89.67%	78.03%	94.51%
R&D to Revenue	25.77%	24.02%	24.95%	27.58%	32.07%	32.31%	35.47%	38.48%	45.50%	57.60%	51.66%
Operating Expenses to Revenue	94.39%	87.34%	87.68%	152.45%	105.93%	106.21%	111.48%	129.71%	133.18%	128.00%	144.12%
Earnings before Interest and Taxes (EBIT)	-42	-35	-38	-89	-49	-47	-50	-61	-62	-45	-57
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-35	-28	-32	-81	-41	-39	-42	-52	-55	-39	-52
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.32	6.05	5.60	5.84	3.54	3.59	1.87	1.76	1.22	1.80	2.52
Price to Tangible Book Value (P/TBV)	6.88	7.75	7.11	7.35	4.70	4.69	2.41	2.24	1.53	2.24	3.09
Price to Revenue (P/Rev)	6.74	8.35	8.46	9.72	7.15	8.06	4.74	4.92	3.76	6.24	9.76
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	11.39	13.44	12.08	12.79	6.34	6.47	2.88	2.66	1.49	2.95	5.21
Enterprise Value to Revenue (EV/Rev)	6.00	7.53	7.57	8.74	6.09	6.88	3.37	3.40	2.06	4.21	7.28
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.55	-0.56	-0.56	-0.56	-0.54	-0.56	-0.60	-0.60	-0.63	-0.62	-0.72
Leverage Ratio	1.30	1.28	1.27	1.26	1.23	1.23	1.23	1.21	1.20	1.24	1.21
Compound Leverage Factor	1.22	1.16	1.15	1.21	1.13	1.12	1.13	1.13	1.13	1.15	1.08
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	6.83	8.81	9.23	9.61	6.79	7.51	3.34	3.44	2.52	4.28	6.37
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.51	4.96	4.88	4.91	5.51	5.98	5.79	6.12	6.79	6.46	6.58
Quick Ratio	4.10	4.45	4.38	4.36	4.88	5.31	5.19	5.49	6.04	5.76	6.01
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	55	70	65	36	15	-4.17	-38	-50	-101	-121	-220
Operating Cash Flow to CapEx	-313.37%	-944.80%	-765.23%	-660.93%	-3,221.06%	-1,525.43%	-865.19%	-519.23%	-489.21%	-457.29%	-7.70%
Free Cash Flow to Firm to Interest Expense	382.77	2,897.22	2,258.58	0.00	0.00	0.00	-37,679.70	-49,865.70	-50,251.95	-121,380.00	-8,788.67
Operating Cash Flow to Interest Expense	-90.81	-892.83	-528.28	0.00	0.00	0.00	-20,704.00	-23,412.00	-22,144.00	-54,070.00	-50.68
Operating Cash Flow Less CapEx to Interest Expense	-119.79	-987.33	-597.31	0.00	0.00	0.00	-23,097.00	-27,921.00	-26,670.50	-65,894.00	-709.16
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.54	0.49	0.45	0.41	0.36	0.32	0.28	0.26	0.24	0.25	0.24
Accounts Receivable Turnover	8.09	8.84	7.93	7.92	6.59	6.58	5.81	5.62	5.49	5.58	5.91
Inventory Turnover	7.23	6.73	6.40	5.42	4.87	4.47	4.35	3.64	3.16	2.87	3.36
Fixed Asset Turnover	3.18	2.91	2.67	2.39	2.07	1.94	1.81	1.76	1.91	2.06	2.22
Accounts Payable Turnover	23.51	21.83	22.91	18.67	16.35	11.47	9.10	8.71	8.90	5.64	6.82
Days Sales Outstanding (DSO)	45.11	41.27	46.05	46.10	55.36	55.50	62.81	64.93	66.53	65.38	61.72
Days Inventory Outstanding (DIO)	50.46	54.24	57.04	67.40	74.93	81.74	83.83	100.22	115.39	127.20	108.75
Days Payable Outstanding (DPO)	15.53	16.72	15.93	19.55	22.32	31.81	40.10	41.92	41.03	64.75	53.52
Cash Conversion Cycle (CCC)	80.04	78.80	87.15	93.94	107.97	105.43	106.53	123.23	140.89	127.83	116.95
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	183	185	196	202	267	279	287	300	316	308	284
Invested Capital Turnover	1.55	1.42	1.30	1.18	0.95	0.89	0.86	0.79	0.79	0.82	1.05
Increase / (Decrease) in Invested Capital	-84	-94	-91	-99	-49	-29	2.60	7.32	57	90	180
Enterprise Value (EV)	2,085	2,487	2,371	2,580	1,690	1,804	826	800	470	908	1,481
Market Capitalization	2,342	2,758	2,647	2,869	1,984	2,116	1,163	1,157	857	1,347	1,986
Book Value per Share	$7.38	$7.68	$8.07	$8.44	$9.69	$10.26	$10.86	$11.62	$12.38	$13.19	$14.01
Tangible Book Value per Share	$5.71	$6.00	$6.36	$6.71	$7.31	$7.84	$8.42	$9.12	$9.87	$10.64	$11.42
Total Capital	440	456	473	491	560	590	623	658	704	746	789
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-257	-271	-276	-289	-293	-311	-336	-357	-388	-439	-505
Capital Expenditures (CapEx)	4.14	2.27	2.00	0.97	0.60	1.51	2.39	4.51	9.05	12	16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	6.32	4.84	-0.63	-1.34	11	14	15	16	30	19	0.85
Debt-free Net Working Capital (DFNWC)	263	276	276	288	304	325	351	373	417	458	506
Net Working Capital (NWC)	263	276	276	288	304	325	351	373	417	458	506
Net Nonoperating Expense (NNE)	10	7.34	9.42	23	11	10	11	15	16	11	11
Net Nonoperating Obligations (NNO)	-257	-271	-276	-289	-293	-311	-336	-357	-388	-439	-505
Total Depreciation and Amortization (D&A)	6.40	6.38	6.66	8.30	8.30	8.17	8.50	8.49	7.03	5.29	4.95
Debt-free, Cash-free Net Working Capital to Revenue	1.82%	1.46%	-0.20%	-0.46%	3.98%	5.28%	5.92%	6.61%	12.95%	8.95%	0.42%
Debt-free Net Working Capital to Revenue	75.78%	83.49%	88.11%	97.58%	109.69%	123.87%	143.17%	158.29%	183.09%	212.25%	248.48%
Net Working Capital to Revenue	75.78%	83.49%	88.11%	97.58%	109.69%	123.87%	143.17%	158.29%	183.09%	212.25%	248.48%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.66)	($0.53)	($0.59)	($1.47)	($0.79)	($0.75)	($0.81)	($1.01)	($1.04)	($0.74)	($0.92)
Adjusted Weighted Average Basic Shares Outstanding	59.65M	59.16M	58.02M	58.15M	57.78M	57.50M	56.89M	57.04M	56.78M	56.44M	53.89M
Adjusted Diluted Earnings per Share	($0.66)	($0.53)	($0.59)	($1.47)	($0.79)	($0.75)	($0.81)	($1.01)	($1.04)	($0.74)	($0.92)
Adjusted Weighted Average Diluted Shares Outstanding	59.65M	59.16M	58.02M	58.15M	57.78M	57.50M	56.89M	57.04M	56.78M	56.44M	53.89M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	59.92M	59.65M	59.36M	58.59M	58.23M	57.82M	57.67M	57.40M	57.15M	56.86M	56.57M
Normalized Net Operating Profit after Tax (NOPAT)	-29	-24	-25	-31	-34	-33	-35	-34	-43	-31	-40
Normalized NOPAT Margin	-31.35%	-27.34%	-29.78%	-37.80%	-45.45%	-45.99%	-52.40%	-52.83%	-71.69%	-57.59%	-69.47%
Pre Tax Income Margin	-42.19%	-35.50%	-41.02%	-104.81%	-59.95%	-59.98%	-69.41%	-89.07%	-97.18%	-76.96%	-88.69%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-292.38	-1,446.38	-1,322.14	0.00	0.00	0.00	-50,357.00	-60,740.00	-30,971.00	-44,787.00	-2,293.28
NOPAT to Interest Expense	-203.44	-1,010.45	-870.00	0.00	0.00	0.00	-35,077.70	-42,546.70	-21,572.95	-31,241.00	-1,592.39
EBIT Less CapEx to Interest Expense	-321.36	-1,540.88	-1,391.17	0.00	0.00	0.00	-52,750.00	-65,249.00	-35,497.50	-56,611.00	-2,951.76
NOPAT Less CapEx to Interest Expense	-232.42	-1,104.95	-939.04	0.00	0.00	0.00	-37,470.70	-47,055.70	-26,099.45	-43,065.00	-2,250.87
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.01%	-0.79%	-1.90%	-2.31%	-3.18%	-2.83%	-2.15%	-2.34%	-2.81%	-2.89%	-3.56%

Frequently Asked Questions About Twist Bioscience's Financials

When does Twist Bioscience's fiscal year end?

According to the most recent income statement we have on file, Twist Bioscience's financial year ends in September. Their financial year 2024 ended on September 30, 2024.

How has Twist Bioscience's net income changed over the last 7 years?

Twist Bioscience's net income appears to be on an upward trend, with a most recent value of -$208.73 million in 2024, rising from -$59.31 million in 2017. The previous period was -$204.62 million in 2023. Find out what analysts predict for Twist Bioscience in the coming months.

What is Twist Bioscience's operating income?

Twist Bioscience's total operating income in 2024 was -$220.83 million, based on the following breakdown:

Total Gross Profit: $133.35 million
Total Operating Expenses: $354.18 million

How has Twist Bioscience revenue changed over the last 7 years?

Over the last 7 years, Twist Bioscience's total revenue changed from $10.77 million in 2017 to $312.97 million in 2024, a change of 2,806.8%.

How much debt does Twist Bioscience have?

Twist Bioscience's total liabilities were at $141.63 million at the end of 2024, a 7.4% decrease from 2023, and a 429.9% increase since 2018.

How much cash does Twist Bioscience have?

In the past 6 years, Twist Bioscience's cash and equivalents has ranged from $46.74 million in 2019 to $465.83 million in 2021, and is currently $226.32 million as of their latest financial filing in 2024.

How has Twist Bioscience's book value per share changed over the last 7 years?

Over the last 7 years, Twist Bioscience's book value per share changed from 0.00 in 2017 to 8.07 in 2024, a change of 806.8%.

Related Companies

This page (NASDAQ:TWST) was last updated on 5/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Twist Bioscience (TWST) Financials

Frequently Asked Questions About Twist Bioscience's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Twist Bioscience (TWST) Financials

Annual Income Statements for Twist Bioscience

Quarterly Income Statements for Twist Bioscience

Annual Cash Flow Statements for Twist Bioscience

Quarterly Cash Flow Statements for Twist Bioscience

Annual Balance Sheets for Twist Bioscience

Quarterly Balance Sheets for Twist Bioscience

Annual Metrics And Ratios for Twist Bioscience

Quarterly Metrics And Ratios for Twist Bioscience

Frequently Asked Questions About Twist Bioscience's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools